Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2009 1
2016 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O. Kotschy A, et al. Among authors: proszenyak a. Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19. Nature. 2016. PMID: 27760111
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.
Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Murray J, Davidson J, Chen I, Dokurno P, Surgenor AE, Daniels ZM, Hubbard RE, Le Toumelin-Braizat G, Claperon A, Lysiak-Auvity G, Girard AM, Bruno A, Chanrion M, Colland F, Maragno AL, Demarles D, Geneste O, Kotschy A. Szlavik Z, et al. Among authors: proszenyak a. J Med Chem. 2020 Nov 25;63(22):13762-13795. doi: 10.1021/acs.jmedchem.0c01234. Epub 2020 Nov 4. J Med Chem. 2020. PMID: 33146521
The Effect of Core Replacement on S64315, a Selective MCL-1 Inhibitor, and Its Analogues.
Sipos S, Bálint B, Szabó ZB, Ondi L, Csékei M, Szlávik Z, Proszenyák Á, Murray JB, Davidson J, Chen I, Dokurno P, Surgenor AE, Pedder C, Hubbard RE, Maragno AL, Chanrion M, Colland F, Geneste O, Kotschy A. Sipos S, et al. Among authors: proszenyak a. ACS Omega. 2021 Aug 18;6(34):22073-22102. doi: 10.1021/acsomega.1c02595. eCollection 2021 Aug 31. ACS Omega. 2021. PMID: 34497901 Free PMC article.
Oxamides as novel NR2B selective NMDA receptor antagonists.
Barta-Szalai G, Borza I, Bozó E, Kiss C, Agai B, Proszenyák A, Keseru GM, Gere A, Kolok S, Galgóczy K, Horváth C, Farkas S, Domány G. Barta-Szalai G, et al. Among authors: proszenyak a. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3953-6. doi: 10.1016/j.bmcl.2004.05.053. Bioorg Med Chem Lett. 2004. PMID: 15225705